Ost-müük Kymera Therapeutics, Inc. - KYMR CFD
Lisa lemmikuks- Kokkuvõte
- Ajaloolised andmed
- Sündmused
- Tuluaruanne
- Bilanss
- Rahavood
- Omand
Hinnavahe | 0.10 | ||||||||
Pika positsiooni ööpäeva tasu
Long position overnight fee
Mine platvormile | -0.024068% | ||||||||
Lühikese positsiooni ööpäeva tasu
Short position overnight fee
Mine platvormile | 0.001846% | ||||||||
Ööpäeva tasu aeg | 21:00 (UTC) | ||||||||
Min kauplemise kogus | 1 | ||||||||
Valuuta | USD | ||||||||
Tagatis | 20% | ||||||||
Aktsiabörs | United States of America | ||||||||
Kauplemise vahendustasu | 0% |
*Information provided by Capital.com
Eelmine sulgemine* | 29.3 |
Avatud* | 28.89 |
Aastane muutus* | -28.35% |
Päeva ulatus* | 28.42 - 29.62 |
52 nädala ulatus | 13.15-44.75 |
Keskmine maht (10 päeva) | 409.05K |
Keskmine maht (3 kuud) | 10.71M |
Turukapitalisatsioon | 1.62B |
P/E suhtarv | -100.00K |
Ringluses olevad aktsiad | 55.18M |
Tulu | 46.83M |
EPS | -2.88 |
Dividendid (% kasumist) | N/A |
Beeta | -100.00K |
Järgmine tuluaruande kuupäev | May 1, 2023 |
Kõigi andmete allikas on Refinitiv, välja arvatud tärniga märgitud, kus *-ga andmed on esitanud Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Sulgemishind | Change (%) | Avamishind | High | Low |
---|---|---|---|---|---|---|
Mar 27, 2023 | 28.73 | 0.00 | 0.00% | 28.73 | 29.73 | 28.42 |
Mar 24, 2023 | 29.30 | 0.88 | 3.10% | 28.42 | 29.57 | 28.03 |
Mar 23, 2023 | 28.81 | 0.33 | 1.16% | 28.48 | 29.50 | 27.81 |
Mar 22, 2023 | 28.05 | -1.67 | -5.62% | 29.72 | 30.03 | 28.03 |
Mar 21, 2023 | 30.00 | -0.08 | -0.27% | 30.08 | 31.03 | 29.91 |
Mar 20, 2023 | 30.71 | 0.74 | 2.47% | 29.97 | 31.00 | 29.76 |
Mar 17, 2023 | 30.98 | 0.89 | 2.96% | 30.09 | 31.25 | 29.60 |
Mar 16, 2023 | 31.01 | 0.35 | 1.14% | 30.66 | 31.59 | 29.77 |
Mar 15, 2023 | 31.10 | 0.26 | 0.84% | 30.84 | 31.52 | 29.93 |
Mar 14, 2023 | 31.57 | -0.59 | -1.83% | 32.16 | 33.08 | 30.85 |
Mar 13, 2023 | 31.15 | 2.50 | 8.73% | 28.65 | 31.37 | 28.65 |
Mar 10, 2023 | 29.56 | -1.41 | -4.55% | 30.97 | 31.26 | 28.44 |
Mar 9, 2023 | 31.66 | -0.36 | -1.12% | 32.02 | 33.39 | 31.30 |
Mar 8, 2023 | 33.10 | 1.08 | 3.37% | 32.02 | 33.15 | 32.02 |
Mar 7, 2023 | 32.85 | 0.33 | 1.01% | 32.52 | 33.66 | 32.11 |
Mar 6, 2023 | 32.58 | 0.11 | 0.34% | 32.47 | 32.85 | 31.47 |
Mar 3, 2023 | 32.76 | 0.21 | 0.65% | 32.55 | 32.90 | 31.88 |
Mar 2, 2023 | 32.41 | 0.77 | 2.43% | 31.64 | 32.69 | 30.12 |
Mar 1, 2023 | 32.04 | 0.62 | 1.97% | 31.42 | 32.12 | 30.83 |
Feb 28, 2023 | 31.37 | -0.48 | -1.51% | 31.85 | 33.04 | 31.03 |
Kymera Therapeutics, Inc. Events
Kellaaeg (UTC) (UTC) | Riik | Sündmus |
---|---|---|
No events scheduled |
- Aastas
- Kvartalis
2022 | 2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|---|
Kogutulu | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
Tulu | 46.826 | 72.832 | 34.034 | 2.934 | 0 |
Kogu tegevuskulu | 208.082 | 173.362 | 80.338 | 45.139 | 21.451 |
Müük/Üldine/admin kulud, kokku | 43.834 | 36.345 | 18.233 | 7.981 | 3.772 |
Uuringud ja arendus | 164.248 | 137.017 | 62.105 | 37.158 | 17.679 |
Tulud majandustegevusest | -161.256 | -100.53 | -46.304 | -42.205 | -21.451 |
Intressitulud (kulu), muud tulud, neto | 6.448 | 0.313 | 0.711 | 0.959 | -0.016 |
Netotulu enne makse | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
Netotulu pärast makse | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
Netotulu enne erikulusid | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
Netotulu | -154.808 | -100.217 | -45.593 | -41.246 | -21.467 |
Arvestatav tulu, v a erikulud | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
Arvestatav tulu, koos erikuludega | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
Jaotamisele kuuluv netotulu | -154.808 | -100.217 | -54.643 | -41.246 | -21.467 |
Keskmine jaotamisele kuuluv aktsia kohta | 53.9332 | 47.989 | 44.4822 | 43.1386 | 43.1386 |
Jaotatav EPS, v a erakorralised kulud | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -2.87036 | -2.08833 | -1.22842 | -0.95613 | -0.49763 |
Total Adjustments to Net Income | 0 | -9.05 |
Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | Dec 2021 | |
---|---|---|---|---|---|
Kogutulu | 16.139 | 9.551 | 11.514 | 9.622 | 15.275 |
Tulu | 16.139 | 9.551 | 11.514 | 9.622 | 15.275 |
Kogu tegevuskulu | 54.769 | 54.433 | 52.324 | 46.555 | 49.269 |
Müük/Üldine/admin kulud, kokku | 11.636 | 10.556 | 11.031 | 10.611 | 11.74 |
Uuringud ja arendus | 43.133 | 43.877 | 41.293 | 35.944 | 37.529 |
Tulud majandustegevusest | -38.63 | -44.882 | -40.81 | -36.933 | -33.994 |
Intressitulud (kulu), muud tulud, neto | 3.765 | 1.88 | 0.553 | 0.249 | 0.094 |
Netotulu enne makse | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Netotulu pärast makse | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Netotulu enne erikulusid | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Netotulu | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Total Adjustments to Net Income | 0 | ||||
Arvestatav tulu, v a erikulud | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Arvestatav tulu, koos erikuludega | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Jaotamisele kuuluv netotulu | -34.865 | -43.002 | -40.257 | -36.684 | -33.9 |
Keskmine jaotamisele kuuluv aktsia kohta | 57.9326 | 54.5355 | 51.7724 | 51.6511 | 51.4312 |
Jaotatav EPS, v a erakorralised kulud | -0.60182 | -0.78851 | -0.77758 | -0.71023 | -0.65913 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | ||
Jaotamisele kuuluv normaal-EPS | -0.60182 | -0.78851 | -0.77758 | -0.71023 | -0.65913 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Käibevarad kokku | 451.273 | 302.339 | 92.845 | 41.79 |
Raha ja lühiajalised investeeringud | 442.418 | 296.202 | 91.957 | 41.26 |
Raha ja ekvivalendid | 47.976 | 31.004 | 76.015 | 41.26 |
Lühiajalised investeeringud | 394.442 | 265.198 | 15.942 | 0 |
Laekumata arved, neto | 0.135 | 1.433 | 0 | 0.148 |
Prepaid Expenses | 8.72 | 4.704 | 0.888 | 0.382 |
Total Assets | 605.905 | 487.175 | 116.702 | 44.231 |
Property/Plant/Equipment, Total - Net | 21.307 | 20.686 | 22.083 | 2.242 |
Property/Plant/Equipment, Total - Gross | 25.223 | 22.833 | 23.132 | 2.466 |
Accumulated Depreciation, Total | -3.916 | -2.147 | -1.049 | -0.224 |
Other Long Term Assets, Total | 8.138 | 1.619 | 1.774 | 0.199 |
Total Current Liabilities | 92.542 | 110.617 | 34.57 | 4.687 |
Accounts Payable | 4.005 | 4.368 | 3.276 | 2.056 |
Accrued Expenses | 25.08 | 12.896 | 7.175 | 2.225 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.138 | 0.689 | 0.681 | 0.302 |
Other Current Liabilities, Total | 62.319 | 92.664 | 23.438 | 0.104 |
Total Liabilities | 146.267 | 203.287 | 82.028 | 5.238 |
Total Long Term Debt | 1.14 | 0.604 | 1.165 | 0.393 |
Capital Lease Obligations | 1.14 | 0.604 | 1.165 | 0.393 |
Other Liabilities, Total | 52.585 | 92.066 | 46.293 | 0.158 |
Total Equity | 459.638 | 283.888 | 34.674 | 38.993 |
Redeemable Preferred Stock | 109.08 | 73.429 | ||
Common Stock | 0.005 | 0.004 | 0 | 0 |
Additional Paid-In Capital | 689.275 | 412.777 | 2.044 | 0.774 |
Retained Earnings (Accumulated Deficit) | -228.982 | -128.765 | -76.456 | -35.21 |
Other Equity, Total | -0.66 | -0.128 | 0.006 | 0 |
Total Liabilities & Shareholders’ Equity | 605.905 | 487.175 | 116.702 | 44.231 |
Total Common Shares Outstanding | 51.5362 | 44.4822 | 43.1386 | 43.1386 |
Accounts Receivable - Trade, Net | 0.135 | 0.856 | ||
Long Term Investments | 125.187 | 162.531 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Käibevarad kokku | 431.382 | 451.273 | 543.731 | 364.806 | 340.791 |
Raha ja lühiajalised investeeringud | 420.812 | 442.418 | 536.386 | 359.107 | 333.537 |
Raha ja ekvivalendid | 33.733 | 47.976 | 156.819 | 84.903 | 53.098 |
Lühiajalised investeeringud | 387.079 | 394.442 | 379.567 | 274.204 | 280.439 |
Laekumata arved, neto | 1.263 | 0.135 | 1.573 | 0.904 | 1.734 |
Accounts Receivable - Trade, Net | 1.263 | 0.135 | 1.573 | 0.904 | 0.878 |
Prepaid Expenses | 9.307 | 8.72 | 5.772 | 4.795 | 5.52 |
Total Assets | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
Property/Plant/Equipment, Total - Net | 21.066 | 21.307 | 21.724 | 21.766 | 20.502 |
Property/Plant/Equipment, Total - Gross | 25.668 | 25.223 | 24.951 | 24.942 | 23.127 |
Accumulated Depreciation, Total | -4.602 | -3.916 | -3.227 | -3.176 | -2.625 |
Long Term Investments | 102.478 | 125.187 | 74.692 | 45.305 | 101.639 |
Other Long Term Assets, Total | 8.134 | 8.138 | 2.306 | 2.509 | 1.62 |
Total Current Liabilities | 88.339 | 92.542 | 94.493 | 108.685 | 110.137 |
Accounts Payable | 2.567 | 4.005 | 5.033 | 8.177 | 8.348 |
Accrued Expenses | 22.913 | 25.08 | 21.105 | 16.838 | 12.962 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Current Port. of LT Debt/Capital Leases | 1.087 | 1.138 | 1.189 | 1.038 | 0.64 |
Other Current Liabilities, Total | 61.772 | 62.319 | 67.166 | 82.632 | 88.187 |
Total Liabilities | 134.34 | 146.267 | 159.318 | 176.282 | 189.305 |
Total Long Term Debt | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
Capital Lease Obligations | 0.927 | 1.14 | 1.347 | 1.145 | 0.498 |
Other Liabilities, Total | 45.074 | 52.585 | 63.478 | 66.452 | 78.67 |
Total Equity | 428.72 | 459.638 | 483.135 | 258.104 | 275.247 |
Common Stock | 0.005 | 0.005 | 0.005 | 0.005 | 0.004 |
Additional Paid-In Capital | 697.597 | 689.275 | 678.358 | 424.599 | 417.096 |
Retained Earnings (Accumulated Deficit) | -265.666 | -228.982 | -195.082 | -166.5 | -141.84 |
Other Equity, Total | -3.216 | -0.66 | -0.146 | 0 | -0.013 |
Total Liabilities & Shareholders’ Equity | 563.06 | 605.905 | 642.453 | 434.386 | 464.552 |
Total Common Shares Outstanding | 51.6927 | 51.5362 | 51.2565 | 45.3277 | 44.8794 |
- Aastas
- Kvartalis
2021 | 2020 | 2019 | 2018 | |
---|---|---|---|---|
Netotulu/algväärtus | -100.217 | -45.593 | -41.246 | -21.467 |
Raha majandustegevusest | -128.946 | 88.13 | 17.905 | -17.863 |
Raha majandustegevusest | 2.397 | 1.763 | 0.825 | 0.205 |
Mittelikviidsed varad | 30.797 | 7.093 | 1.639 | 1.091 |
Makstud intressid | 0.158 | 0.115 | 0.046 | 0.015 |
Muutused tööjõus | -61.923 | 124.867 | 56.687 | 2.308 |
Tulu investeeringutelt | -99.835 | -422.588 | -16.486 | -1.356 |
Kapitalikulutused | -1.597 | -9.096 | -0.532 | -1.356 |
Muud rahavood investeeringutelt, kokku | -98.238 | -413.492 | -15.954 | 0 |
Rahavood investeeringutelt | 250.28 | 289.262 | 34.911 | 52.932 |
Aktsiate emiteerimine (tagasiost), neto | 249.18 | 276.289 | 35.282 | 53.227 |
Laenu väljastamine (kustutamine), neto | -0.849 | -0.554 | -0.371 | -0.295 |
Rahaline kogumuutus | 21.499 | -45.196 | 36.33 | 33.713 |
Rahavoogudesse investeerimine | 1.949 | 13.527 |
Mar 2022 | Dec 2021 | Sep 2021 | Jun 2021 | Mar 2021 | |
---|---|---|---|---|---|
Net income/Starting Line | -36.684 | -100.217 | -66.317 | -37.735 | -13.075 |
Cash From Operating Activities | -40.295 | -128.946 | -90.594 | -53.334 | -22.823 |
Cash From Operating Activities | 0.687 | 2.397 | 1.708 | 1.037 | 0.485 |
Non-Cash Items | 9.048 | 30.797 | 20.483 | 11.409 | 4.451 |
Cash Interest Paid | 0.046 | 0.158 | 0.106 | 0.054 | 0.024 |
Changes in Working Capital | -13.346 | -61.923 | -46.468 | -28.045 | -14.684 |
Cash From Investing Activities | 25.863 | -99.835 | -31.816 | 105.046 | 44.323 |
Capital Expenditures | -0.482 | -1.597 | -1.096 | -0.79 | -0.164 |
Other Investing Cash Flow Items, Total | 26.345 | -98.238 | -30.72 | 105.836 | 44.487 |
Cash From Financing Activities | 0.185 | 250.28 | 248.226 | 2.187 | 0.595 |
Financing Cash Flow Items | 0 | 1.949 | 1.95 | -0.397 | -0.397 |
Issuance (Retirement) of Stock, Net | 0.449 | 249.18 | 246.969 | 2.925 | 1.147 |
Issuance (Retirement) of Debt, Net | -0.264 | -0.849 | -0.693 | -0.341 | -0.155 |
Net Change in Cash | -14.247 | 21.499 | 125.816 | 53.899 | 22.095 |
Investori nimi | Investori liik | Ringluse protsent | Hoitud osakud | Muutus osakutes | Hoidmise kuupäev | Hinnang käibele |
---|---|---|---|---|---|---|
Atlas Venture | Venture Capital | 10.6159 | 5858262 | -126474 | 2023-01-12 | LOW |
BVF Partners L.P. | Hedge Fund | 8.5779 | 4733611 | 41007 | 2023-01-12 | LOW |
Wellington Management Company, LLP | Investment Advisor/Hedge Fund | 8.3197 | 4591089 | 1180703 | 2022-12-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 7.8899 | 4353945 | 277562 | 2022-12-31 | LOW |
Avoro Capital Advisors LLC | Investment Advisor/Hedge Fund | 6.9767 | 3850000 | 1680770 | 2022-12-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 6.619 | 3652608 | 797130 | 2022-12-31 | LOW |
Vertex Pharmaceuticals Inc | Corporation | 5.8007 | 3201049 | 49928 | 2022-03-31 | |
Baker Bros. Advisors LP | Hedge Fund | 5.2186 | 2879825 | 0 | 2022-12-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 5.1577 | 2846221 | 160817 | 2022-12-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 5.1454 | 2839421 | 172415 | 2022-12-31 | LOW |
Redmile Group, LLC | Investment Advisor/Hedge Fund | 4.8453 | 2673837 | -202800 | 2022-12-31 | LOW |
Invus Public Equities Advisors, LLC | Investment Advisor | 3.6243 | 2000000 | 500000 | 2022-12-31 | LOW |
T. Rowe Price Investment Management, Inc. | Investment Advisor | 3.5445 | 1955977 | -40552 | 2022-12-31 | MED |
Rock Springs Capital Management LP | Hedge Fund | 2.2249 | 1227779 | 181036 | 2022-12-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.5331 | 846046 | 520360 | 2022-12-31 | LOW |
Wasatch Global Investors Inc | Investment Advisor/Hedge Fund | 1.5081 | 832221 | -228340 | 2022-12-31 | LOW |
EcoR1 Capital, LLC | Hedge Fund | 1.4426 | 796093 | 0 | 2022-12-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.3538 | 747071 | 45849 | 2022-12-31 | LOW |
Mellon Investments Corporation | Investment Advisor/Hedge Fund | 1.2316 | 679621 | -41254 | 2022-12-31 | LOW |
Aquilo Capital Management, LLC | Investment Advisor/Hedge Fund | 1.1406 | 629411 | 299165 | 2022-12-31 | LOW |
Miks valida Capital.com? Meie numbrid räägivad iseenda eest.
Capital.com Group500K+
Kauplejad
92K+
Igakuiste aktiivsete klientide arv
$53M+
Igakuine investeerimise maht
$30M+
Igakuiselt välja võetud
Kauplemiskalkulaator
Arvutage oma hüpoteetiline võit/kaotus, kui oleksite avanud CFD-tehingu ühel kindlal kuupäeval (valige kuupäev) ja sulgenud teisel kuupäeval (valige kuupäev).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Kymera Therapeutics, Inc. Company profile
Ettevõttest Kymera Therapeutics, Inc.
Kymera Therapeutics, Inc. on biofarmatseutiline ettevõte. Ettevõte keskendub väikesemolekulaarsete ravimite avastamisele ja arendamisele, mis lagundavad selektiivselt haigusi põhjustavaid valke, kasutades selleks organismi enda loomulikku valkude lagundamise süsteemi. Ettevõtte suunatud valkude lagundamise (TPD) platvorm Pegasus võimaldab avastada selektiivseid väikemolekulaarseid valkude lagundajaid, mis on aktiivsed haigusi põhjustavate valkude vastu kogu organismis. Ettevõtte Pegasuse platvorm hõlmab E3-ligaasi kogu keha atlastikku, E3-ligaasi sidemete tööriistakasti, ternaarse kompleksi modelleerimist, kvantitatiivset süsteemifarmakoloogilist mudelit ja keemiat. Ettevõtte kliinilises staadiumis olevad programmid hõlmavad IRAK4, IRAKIMiD ja STAT3, mis on suunatud interleukiin-1 retseptori/tollitaolise retseptori (IL-1R/TLR) ja januskinaasi/signaaltransduktorite ja transkriptsiooni aktivaatorite (JAK/STAT) sihtmärkidele. Tema programmid keskenduvad mitmesuguste immuunsüsteemi põletikuliste haiguste, hematoloogiliste pahaloomuliste kasvajate ja soliidtuumorite ravile.
Industry: | Biotechnology & Medical Research (NEC) |
200 Arsenal Yards Blvd., Suite 230
2Nd Floor
WATERTOWN
MASSACHUSETTS 02472
US
Tuluaruanne
- Annual
- Quarterly
Teised on vaadanud veel
Kas otsite jätkuvalt vahendajat, keda saab usaldada?
Ühinege 500,000+ kauplejaga üle kogu maailma, kes valisid kauplemiseks veebisaidi Capital.com